A Phase II Study of Carboplatin-Cisplatin-Etoposide Combination Chemotherapy in Advanced Non-Small-Cell Lung Cancer

Abstract

It is reported that the combination of cisplatin (CDDP) and carboplatin (CBDCA) is synergistic in vitro. The objective of this study was to evaluate the therapeutic effect and safety of the two platinum compounds in combination with etoposide in the treatment of non-small-cell lung cancer (NSLC). Forty patients were registered. Based on the results of a phase I study, patients were treated with CDDP (80 mg/m2 i.v. on day 1), CBDCA (280 mg/m2 i.v. on day 1), and etoposide (80 mg/m2 i.v. on days 1-3). Of the 40 patients, 30 were men and 10 women. Histology revealed adenocarcinoma(AC) (n = 20), squamous cell carcinoma(SCC) (n = 18), and large cell carcinoma(LCC) (n = 2). Staging: IIIA (n = 3); IIIB (n = 17); and IV (n = 20). A 32.5% overall response rate [13 of 40; 95% confidence interval (CI) 18-47%] was achieved. The response rates in patients with SCC and AC were 55.6 and 10.0% (p < 0.005), respectively. The median duration of response was 47.1 weeks and the overall median survival time was 57.1 weeks. Leukopenia and thrombocytopenia--World Health Organization (WHO) grade IV--occurred in nine and 11 patients, respectively. Nonhematological toxicities were mainly nausea, vomiting, and alopecia. In conclusion, further investigations of this regimen are warranted in the treatment of NSLC.

The pemetrexed-containing treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis

“…This scale has been adopted in other non-randomized studies [28,32,33]. Studies which met five or more of the eight criteria were given higher quality scores.…”

Establishment and characterization of a cisplatin-resistant cell line, KB-R, derived from oral carcinoma cell line, KB

“…Platinum analogues are key anticancer agents used in the chemotherapy of solid tumors, such as ovary (1), advanced bladder carcinoma (2), testis (3), head and neck carcinoma (4-6), and lung carcinoma (7). Cisplatin (CDDP) is one of the platinum analogues and the mechanism of CDDP anti-cancer activity is believed to be the binding to DNA, interfering in the cell repair mechanism, eventually leading to cell death (7). However, the effectiveness of CDDP in the treatment of cancer is limited because of acquired or intrinsic resistance (8,9).…”

“…Cisplatin or cis-Diamminedichloroplatinum (II) (CDDP) is one of the platinum analogues and the first choice among anti-tumor agents for the chemotherapy of many malignancies (1)(2)(3)(4)(5)(6)(7). The mechanism of cisplatin anticancer activity is believed to be the binding to DNA, interfering in the cell repair mechanism, eventually leading to cell death (7). However, its effectiveness in the treatment of oral SCC is limited because of acquired or intrinsic resistance (8,9).…”

The Pemetrexed-Containing Treatments in the Non-small Cell Lung Cancer, Is -/Low Thymidylate Synthase Expression Better than +/High Thymidylate Synthase Expression? A Meta-analysis

“…This scale has been adopted in other nonrandomized studies [28,32,33]. Studies which met five or more of the eight criteria were given higher quality scores.…”